Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): A matched-pair study comparing oral fluoroquinolones and intravenous piperacillin-tazobactam

Bone Marrow Transplantation

Volumn 36, Issue 1, 2005, Pages 59-65

  Solano, Carlos ^a   Gutierrez, A ^a   Martinez, F ^b   Gimeno, C ^a   Gomez C ^a   Munoz I ^a   Faus, F ^b   Goterris, R ^a   Farga, A ^a   Navarro, D ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Antibacterial prophylaxis; Early bacterial infections; Peripheral blood stem cell transplantation; Piperacillin tazobactam

Indexed keywords

ACICLOVIR; AMIKACIN; AMINOTRANSFERASE; AMPHOTERICIN B; BUSULFAN; CARBOPLATIN; CEFALOTIN; CEFTAZIDIME; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; IMIPENEM; LIVER ENZYME; MELPHALAN; NORFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTEREMIA; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION COMPLICATION; INFECTION PREVENTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; BACTEREMIA; BACTERIAL INFECTIONS; FEMALE; FEVER; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; NEUTROPENIA; PENICILLANIC ACID; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PIPERACILLIN; PREMEDICATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 21744431864     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705005     Document Type: Article

References (29)

1. Engels EA, Ellis CA, Supran SE et al. Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis 1999; 28: 256-266.
2. Kruger W, Russmann B, Kroger N et al. Early infections in patients undergoing bone marrow or blood stem cell transplantation - a 7 year single centre investigation of 409 cases. Bone Marrow Transplant 1999; 23: 589-597.
3. Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001; 32: 391-395.
4. Saavedra S, Jarque I, Sanz GF et al. Infectious complications in patients undergoing unrelated donor bone marrow transplantation: experience from a single institution. Clin Microbiol Infect 2002; 8: 725-733.
5. Buzyn A, Tancrede C, Nitenberg G, Cordonnier C. Reflections on gut decontamination in hematology. Clin Microbiol Infect 1999; 5: 449-456.
6. Kerr KG. The prophylaxis of bacterial infections in neutropenic patients. J Antimicrobial Chemother 1999; 44: 587-591.
7. Sepkowitz KA. Antibiotic prophylaxis in patients receiving hematopoietic stem cell transplant. Bone Marrow Transplant 2002; 29: 367-371.
8. Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23: 795-805.
9. Horvathova Z, Spanik S, Sufliarsky J et al. Bacteremia due to methicillin-resistant staphylococci occurs more frequently in neutropenic patients who received antimicrobial prophylaxis and is associated with higher mortality in comparison to methicillin-sensitive bacteriemia. Int J Antimicrobial Agents 1998; 10: 55-58.
10. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14: 1201-1207.
11. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002; 34: 1524-1529.
12. Yeh SP, Hsueh EJ, Yu MS et al. Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal. Bone Marrow Transplant 1999; 24: 1207-1211.
13. van Kraaij MG, Dekker AW, Peters E et al. Emergence and infectious complications of ciprofloxacin-resistant Escherichia coli in haematological cancer patients. Eur J Clin Microbiol Infect Dis 1998; 17: 591-592.
14. Oethinger M, Conrad S, Kaifel K et al. Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrobial Agents Chemother 1996; 40: 387-392.
15. Baum HV, Franz U, Geiss HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 2000; 28: 278-281.
16. Avril M, Hartmann O, Valteau-Couanet D et al. Antiinfective prophylaxis with ceftazidime and teicoplanin in children undergoing high-dose chemotherapy and bone marrow transplantation. Pediatr Hematol Oncol 1994; 11: 63-73.
17. Kroschinsky F, Wichmann G, Bornhauser M et al. Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation. Transpl Infect Dis 2002; 4: 132-136.
18. Meisenberg B, Gollard R, Brehm T et al. Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue. Support Care Cancer 1996; 4: 364-369.
19. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard, 5th edn. Clinical and Laboratory Standards Institute: Wayne, PA, 2000 (http://www.nccls.org).
20. Bauernfeind A, Abele-Horn M, Emmerling P, Jungwirth R. Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. J Antimicrobial Chemother 1994; 34: 1074-1076.
21. Sanders CC, Sanders Jr WE, Goering RV, Werner V. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrobial Agents Chemother 1984; 26: 797-801.
22. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
23. Karp JE, Dick JD, Angelopulos C et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 1986; 81: 237-242.
24. Petersen F, Thornquist M, Buckner C et al. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study. Infection 1988; 16: 199-208.
25. Jagannath S, Vesole DH, Zhang M et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997; 20: 445-450.
26. Meisenberg BR, Ferran K, Hollenbach K et al. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998; 21: 927-932.
27. Chandrasekar PH, Abraham OC, Klein J et al. Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer. Clin Infect Dis 2001; 32: 546-551.
28. Rovira M. Outpatient management of autologous haematopoietic cell transplantation: the Barcelona experience. Presse Med 2004; 33: 479-481.
29. Sanz MA, Lopez J, Lahuerta JJ et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrobial Chemother 2002; 50: 79-88.